US98943L1070 - ZNTL (XNAS)
ZENTALIS PHARMACEUTICALS INC Aktie
4,21 USD
Aktuelle Kurse von ZENTALIS PHARMACEUTICALS INC
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung | Tagesveränderung % |
---|---|---|---|---|---|---|
NASDAQ |
ZNTL
|
USD
|
20.09.2024 16:18
|
4,21 USD
| 4,36 USD | -3,44 % |
Performance
Tag | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
-3,44 % | 29,94 % | 31,15 % | 0,24 % | -69,76 % | -81,01 % | -81,85 % |
Firmenprofil zu ZENTALIS PHARMACEUTICALS INC Aktie
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Investierte Fonds
Folgende Fonds haben in ZENTALIS PHARMACEUTICALS INC investiert:
Fonds | Vol. in Mio 88,86 | Anteil (%) 0,21 % |
Unternehmensdaten zur ZENTALIS PHARMACEUTICALS INC Aktie
Name ZENTALIS PHARMACEUTICALS INC
Firma Zentalis Pharmaceuticals, Inc.
Symbol ZNTL
Website https://zentalis.com
Heimatbörse
NASDAQ
ISIN US98943L1070
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Kimberly Lynn Blackwell M.D.
Marktkapitalisierung 210 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 1359 Broadway, 10018 New York
IPO Datum 2020-04-03
Ticker Symbole
Name | Symbol |
---|---|
NASDAQ | ZNTL |
Weitere Aktien
Investoren die ZENTALIS PHARMACEUTICALS INC halten haben auch folgende Aktien im Depot:
Die Finanzplattform goSPATZ trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
All rights reserved © LCP GmbH 2024